StrideBio is a technology company.
StrideBio has raised $98.0M across 2 funding rounds.
StrideBio has raised $98.0M in total across 2 funding rounds.
StrideBio is a gene therapy company developing next-generation adeno-associated virus (AAV)-based genetic medicines for life-threatening diseases, particularly rare monogenic disorders in CNS and cardiovascular areas.[1][3][5] It builds advanced AAV vectors via its proprietary STRIVE capsid platform, which improves tissue targeting, evades neutralizing antibodies, enhances safety, and boosts gene transfer efficiency compared to first-generation therapies.[2][3][5] Serving patients with conditions like Niemann-Pick type C, Rett syndrome, Angelman syndrome, Dravet syndrome, and alternating hemiplegia of childhood, StrideBio addresses key limitations in existing gene therapies, such as immune evasion and off-target effects.[2][5][6] The company operates from a 40,000 sq ft facility in Research Triangle Park, NC, with in-house manufacturing at 1000L scale and a pipeline in preclinical/clinical stages, backed by $48M in partnerships and $15.7M Series A funding.[2][5]
Founded in 2015 in Research Triangle Park, North Carolina, StrideBio emerged from groundbreaking AAV research by Mavis Agbandje-McKenna, Ph.D., and Aravind Asokan, Ph.D., experts in viral structure and vector engineering.[1][5] The idea stemmed from their work on structure-inspired AAV capsid design to overcome first-generation therapy hurdles like antibody neutralization and poor tissue specificity.[5] Early traction included a multi-technology license from Duke University for cross-species evolved AAV vectors and antibody-evasion tech, fueling an initial program for pediatric alternating hemiplegia of childhood (AHC).[5] By 2018-2019, it secured $15.7M Series A funding and a $48M partnership, expanding its pipeline while building in-house capabilities.[2]
StrideBio rides the gene therapy boom, fueled by AAV advancements for durable, one-time treatments in rare genetic diseases amid rising demand for precision medicines.[1][3] Timing aligns with maturing platforms post-Zolgensma/Luxturna approvals, where next-gen vectors address ~70% patient ineligibility from pre-existing antibodies and immunogenicity.[5] Market forces like orphan drug incentives, accelerating preclinical-to-clinical transitions, and Big Pharma partnerships (e.g., $48M deal) favor it.[2] As a leader in capsid evolution, StrideBio influences the ecosystem by expanding treatable indications in CNS/cardio, licensing tech, and setting standards for safer, targeted delivery.[3][5]
StrideBio's near-term catalysts include advancing lead candidates like STRX-110 and ARVC into clinics, leveraging STRIVE for first-in-class profiles in underserved rare diseases.[2][5] Trends like AI-driven vector design, combo therapies, and regulatory fast-tracks for orphans will accelerate its pipeline, potentially yielding partnerships or buyouts as gene therapy M&A heats up.[3] Its influence may grow via platform licensing, solidifying leadership in AAV evolution and delivering curative therapies that transform lives—echoing its mission to pioneer genetic medicines for the untreatable.[3]
StrideBio has raised $98.0M in total across 2 funding rounds.
StrideBio's investors include Advanced Technology Ventures, Northpond Ventures, Novo Ventures, RA Capital, Venrock, Abingworth.
StrideBio has raised $98.0M across 2 funding rounds. Most recently, it raised $82.0M Series B in March 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Mar 1, 2021 | $82.0M Series B | Advanced Technology Ventures, Northpond Ventures, Novo Ventures, RA Capital, Venrock | |
| Jun 1, 2018 | $16.0M Series A | Abingworth |